120 related articles for article (PubMed ID: 33419846)
1. Accelerated Fractionation With Concomitant Boost
Narvaez CA; Schild SE; Janssen S; Schroeder U; Bruchhage KL; Hakim SG; Rades D
Anticancer Res; 2021 Jan; 41(1):477-484. PubMed ID: 33419846
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Conventional Fractionation and Accelerated Fractionation With Concomitant Boost for Radiotherapy of Non-metastatic Stage IV Head-and-Neck Cancer.
Narvaez C; Schild SE; Rades D
In Vivo; 2021; 35(1):411-415. PubMed ID: 33402490
[TBL] [Abstract][Full Text] [Related]
3. Accelerated Fractionation Plus Chemotherapy
Rades D; Narvaez CA; Janssen S; SchrÖder U; Bruchhage KL; Hakim SG; Bartscht T; Schild SE
Anticancer Res; 2021 Feb; 41(2):877-884. PubMed ID: 33517293
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Carboplatin/Paclitaxel-Based Radiochemotherapy in Locally Advanced Squamous Cell Carcinoma of Head and Neck.
Maring S; Elsayad K; Stenner M; Rudack C; Haverkamp U; Rehkämper J; Wardelmann E; Eich HT
Oncol Res Treat; 2018; 41(12):736-743. PubMed ID: 30419553
[TBL] [Abstract][Full Text] [Related]
5. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial.
Bourhis J; Sire C; Graff P; Grégoire V; Maingon P; Calais G; Gery B; Martin L; Alfonsi M; Desprez P; Pignon T; Bardet E; Rives M; Geoffrois L; Daly-Schveitzer N; Sen S; Tuchais C; Dupuis O; Guerif S; Lapeyre M; Favrel V; Hamoir M; Lusinchi A; Temam S; Pinna A; Tao YG; Blanchard P; Aupérin A
Lancet Oncol; 2012 Feb; 13(2):145-53. PubMed ID: 22261362
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin superior to carboplatin in adjuvant radiochemotherapy for locally advanced cancers of the oropharynx and oral cavity.
Rades D; Ulbricht T; Hakim SG; Schild SE
Strahlenther Onkol; 2012 Jan; 188(1):42-8. PubMed ID: 22194029
[TBL] [Abstract][Full Text] [Related]
7. Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck: Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks.
Rades D; Strojan P; Seidl D; Janssen S; Bajrovic A; Kazic N; Hakim SG; Wollenberg B; Schild SE
J Craniomaxillofac Surg; 2016 Sep; 44(9):1436-40. PubMed ID: 27499514
[TBL] [Abstract][Full Text] [Related]
8. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
[TBL] [Abstract][Full Text] [Related]
9. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Staar S; Rudat V; Stuetzer H; Dietz A; Volling P; Schroeder M; Flentje M; Eckel HE; Mueller RP
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1161-71. PubMed ID: 11483325
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of prognostic factors and two radiation techniques in patients treated with surgery followed by radio(chemo)therapy or definitive radio(chemo)therapy for locally advanced head-and-neck cancer.
Rades D; Stoehr M; Meyners T; Bohlen G; Nadrowitz R; Dunst J; Schild SE; Wroblewski J; Albers D; Schmidt R; Alberti W; Tribius S
Strahlenther Onkol; 2008 Apr; 184(4):198-205. PubMed ID: 18398584
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09.
Fu KK; Clery M; Ang KK; Byhardt RW; Maor MH; Beitler JJ
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):589-97. PubMed ID: 7790243
[TBL] [Abstract][Full Text] [Related]
12. Nuclear expression of p65 (RelA) in patients receiving post-operative radiotherapy for locally advanced squamous cell carcinoma of the head and neck.
Rades D; Huttenlocher S; Seibold ND; Gebhard MP; Thorns C; Hasselbacher K; Wollenberg B; Schild SE
BMC Cancer; 2015 Mar; 15():102. PubMed ID: 25868613
[TBL] [Abstract][Full Text] [Related]
13. Impact of average weekly dose of radiation during radiotherapy alone or chemoradiotherapy in head and neck cancer.
Dragovic AF; Bonner JA; Spencer SA; Nabell LM; Carroll WR; Caudell JJ
Head Neck; 2011 Nov; 33(11):1551-6. PubMed ID: 21990218
[TBL] [Abstract][Full Text] [Related]
14. Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck.
Weiss J; Gilbert J; Deal AM; Weissler M; Hilliard C; Chera B; Murphy B; Hackman T; Liao JJ; Grilley Olson J; Hayes DN
Oral Oncol; 2018 Sep; 84():46-51. PubMed ID: 30115475
[TBL] [Abstract][Full Text] [Related]
15. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
[TBL] [Abstract][Full Text] [Related]
16. Decrease in treatment intensity predicts worse outcome in patients with locally advanced head and neck squamous cell carcinoma undergoing radiochemotherapy.
Mollnar S; Pondorfer P; Kasparek AK; Reinisch S; Moik F; Stotz M; Halm M; Szkandera J; Terbuch A; Eisner F; Gerger A; Kapp KS; Partl R; Vasicek S; Weiland T; Pichler M; Stöger H; Thurnher D; Posch F
Clin Transl Oncol; 2021 Mar; 23(3):543-553. PubMed ID: 32671728
[TBL] [Abstract][Full Text] [Related]
17. Synchronous chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck using capecitabine: a single-centre, open-label, single-group phase II study.
Jegannathen A; Mais K; Sykes A; Lee L; Yap B; Birzgalis A; Homer J; Ryder WD; Slevin N
Clin Oncol (R Coll Radiol); 2011 Mar; 23(2):149-58. PubMed ID: 20951012
[TBL] [Abstract][Full Text] [Related]
18. Prospective randomized trial to compare accelerated (six fractions a week) radiotherapy against concurrent chemoradiotherapy (using conventional fractionation) in locally advanced head and neck cancers.
Gupta M; Mahajan R; Kaushal V; Seem RK; Gupta M; Bhattacharyya T
J Cancer Res Ther; 2015; 11(4):723-9. PubMed ID: 26881508
[TBL] [Abstract][Full Text] [Related]
19. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.
Seiwert TY; Melotek JM; Blair EA; Stenson KM; Salama JK; Witt ME; Brisson RJ; Chawla A; Dekker A; Lingen MW; Kocherginsky M; Villaflor VM; Cohen EE; Haraf DJ; Vokes EE
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):21-9. PubMed ID: 27511844
[TBL] [Abstract][Full Text] [Related]
20. A prospective, multicenter DAHANCA study of hyperfractionated, accelerated radiotherapy for head and neck squamous cell carcinoma.
Saksø M; Andersen E; Bentzen J; Andersen M; Johansen J; Primdahl H; Overgaard J; Eriksen JG
Acta Oncol; 2019 Oct; 58(10):1495-1501. PubMed ID: 31519130
[No Abstract] [Full Text] [Related]
[Next] [New Search]
